ReviewClinical & translational immunology2021
Cardiovascular disease in SARS-CoV-2 infection.
Review in Clinical & translational immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 48 citations in OpenAlex.
- Transthyretin Amyloidosis-One of the Causes of Heart Failure in Patients with Severe Clinical Course of COVID-19.International journal of molecular sciences · 2025Article
- Article
- Review
- Pharmacotherapy from Pre-COVID to Post-COVID: Longitudinal Trends and Predictive Indicators for Long COVID Symptoms.Biomedicines · 2024Article
- The involvement of circulating miR-146a and miR-27a in patients with atherosclerotic cardiovascular disease after SARS-CoV-2 infection.Clinical cardiology · 2024Article
- Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.European journal of medicinal chemistry · 2024Article
- New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic.Frontiers in immunology · 2024Review
- High Risk of Heart Tumors after COVID-19.Life (Basel, Switzerland) · 2023Article
- Substances of abuse and their effect on SAR-CoV-2 pathogenesis.NeuroImmune pharmacology and therapeutics · 2023Review
- The Cardiac Comeback-Beating Stronger: Exploring the Remarkable Resilience of the Heart in COVID-19 Recovery through Cardiac Autonomic Analysis.Medicina (Kaunas, Lithuania) · 2023Article
- Stress native T1 and native T2 mapping compared to myocardial perfusion reserve in long-term follow-up of severe Covid-19.Scientific reports · 2023Article
- Transcriptomic profiling of cardiac tissues from SARS-CoV-2 patients identifies DNA damage.Immunology · 2023Article
- Alterations in Circulating miRNA Levels after Infection with SARS-CoV-2 Could Contribute to the Development of Cardiovascular Diseases: What We Know So Far.International journal of molecular sciences · 2023Review
- Isolated Severe Dysphonia as a Presentation of Post-COVID-19 Syndrome.Diagnostics (Basel, Switzerland) · 2022Article
- Long-term mortality following SARS-CoV-2 infection: A national cohort study from Estonia.The Lancet regional health. Europe · 2022Article
- Sars-Cov-2 Spike Protein-Induced Damage of hiPSC-Derived Cardiomyocytes.Advanced biology · 2022Article
- Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.Nature communications · 2022Article
- Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity.Research square · 2022Article
- Immune response to a conserved enteroviral epitope of the major capsid VP1 protein is associated with lower risk of cardiovascular disease.EBioMedicine · 2022Article
- Effect of Fucoidan on the Mitochondrial Membrane Potential (ΔΨm) of Leukocytes from Patients with Active COVID-19 and Subjects That Recovered from SARS-CoV-2 Infection.Marine drugs · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID-19 and is strongly associated with poor disease outcomes. However, SARS-CoV-2 infection can also trigger
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.